Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Latest Information Update: 30 Nov 2023
Price :
$35 *
At a glance
- Drugs Mazdutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Innovent Biologics
- 22 Nov 2023 Status changed from active, no longer recruiting to completed.
- 16 Oct 2022 Results presented in an Innovent Biologics media release.
- 16 Oct 2022 According to an Innovent Biologics media release, results from the trial have been published online in eClinicalMedicine.